Severe respiratory viral infections, including COVID-19, are now linked to a heightened risk of developing lung cancer. Findings suggest these infections leave a lasting biological impact, creating an environment that promotes tumor growth.
Experimental models confirm that prior viral pneumonia consistently accelerates lung tumor growth. Conversely, vaccination appears to reduce infection-related tumor progression, offering a potential protective effect against long-term oncological consequences.
The mechanism involves viral infections reprogramming the lung's microenvironment. This leads to an accumulation of tumor-associated neutrophils and increased immunosuppression, impairing the body's natural defenses like CD8+ T cell activity.
Preclinical models show promise in targeting this post-viral pro-tumor state. Combined therapies blocking neutrophil recruitment and PD-L1 restored T cell function and reduced tumor growth. These strategies could offer a novel approach to limit lung cancer progression after viral infections.
These results underscore the need for increased clinical vigilance in patients with a history of severe viral pneumonia. Enhanced surveillance and preventative measures like vaccination may be crucial in reducing long-term cancer risk.